Clinical trials
Neuroblastoma trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 1 |
| 2004 | 3 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 3 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Active, not recruiting | 11 |
| Recruiting | 4 |
| Terminated | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Oncology Group | 21 |
| National Cancer Institute (NCI) | 11 |
| Novartis Pharmaceuticals | 5 |
| Eli Lilly and Company | 2 |
| AbbVie | 1 |
| Bristol-Myers Squibb | 1 |
| Cellectar Biosciences, Inc. | 1 |
| GlaxoSmithKline | 1 |
| Instituto de Investigacion Sanitaria La Fe | 1 |
| Merck Sharp & Dohme LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuroblastoma | 49 |
| Sarcoma | 13 |
| Medulloblastoma | 12 |
| Osteosarcoma | 11 |
| Rhabdomyosarcoma | 10 |
| Glioma | 9 |
| Central Nervous System Neoplasms | 8 |
| Sarcoma, Ewing | 8 |
| Wilms Tumor | 8 |
| Astrocytoma | 7 |
Trials
Showing 51 to 49 of 49. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.